Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Light-Touch Study
ISRCTN10012824Phase 3Active, not recruiting
- Sponsor
- Moorfields Eye Hospital
- Start
- Nov 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial of faricimab in exudative macular degeneration (2 arms), sponsored by Moorfields Eye Hospital. Primary endpoint: Change in best corrected visual acuity. Started Nov 2024; status: active, not recruiting.
02
Drugs
faricimab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on ISRCTN10012824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN10012824.